Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002American Medical Association
To the Editor: The Women's Health Initiative (WHI) investigators1 stopped the estrogen plus progestin vs placebo arm of their study because they found that women receiving estrogen plus progestin had a significantly higher risk of breast cancer, coronary heart disease (CHD), stroke, and pulmonary embolus (PE). The authors claim, based on these results, that this hormone replacement therapy (HRT) should not be recommended for primary prevention of CHD in women.
Radford N, Church T. Risks of Postmenopausal Hormone Replacement. JAMA. 2002;288(22):2819. doi:10.1001/jama.288.22.2819
Customize your JAMA Network experience by selecting one or more topics from the list below.